Loading clinical trials...

COMPLETED

Measles, Mumps, and Rubella (MMR) Immunity in College Students

Persistence of Humoral and Cellular Immune Responses Following Age-appropriate Vaccination With the MMR Vaccine

NCT00962819•Sri Edupuganti, MD MPH

Summary

This study will lay the foundation for determining the underlying reasons for lack of immunity to mumps that led to the 2006 mumps outbreak on college campuses in the Mid West, and it will assess the potential for similar outbreaks of measles and rubella. A total of 70 to 80 college students (age 18 to 22) on the Emory campus (or nearby college campuses or the community) will be assessed for antibodies to measles, mumps or rubella by drawing a one-time blood sample. Their medical records will be verified for documentation of immunization with MMR vaccine prior to enrollment in the study. If a study volunteer is found to not have MMR immunity, they will be offered an MMR-II vaccine. For this group, additional blood specimens will be obtained.

Detailed Description

No additional description needed.

Eligibility

Age

18 - 24 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Ability and willing to provide an informed consent
•Documented receipt of MMR-II vaccination in childhood
•Not pregnant

Exclusion Criteria

•No history of HIV infection.
•Immunocompromised health status due to HIV infection, cancer, diabetes, liver, lung or kidney diseases, autoimmune diseases, history of splenectomy.
•Use of immunosuppressive medications within last 2 to 3 months (oral or parenteral corticosteroids or cytotoxic medications)
•Medical conditions that require the use of immunosuppressive medications
•Received blood or blood products within the last 30 days
•Any vaccines received in the last 30 days

Locations (1)

The Hope Clinic of the Emory Vaccine Center

Decatur, Georgia, United States

Key Dates

Start Date

March 1, 2010

Primary Completion Date

December 1, 2012

Completion Date

December 1, 2012

Last Updated

October 8, 2021

Enrollment

ACTUAL participants

Conditions

MeaslesMumpsRubella

Interventions

MMR vaccine

BIOLOGICAL

Prospective Clinical Registry for Evaluation of Exanthematous Infections and Coinfections

NCT07112846

ExanthemaDengue Fever+3 more

View study

COMPLETEDPHASE4

Vaccine Campaign Effects on General Hospital Admissions and Mortality Among Children

NCT03460002

Measles VaccinationOral Polio Vaccine+4 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 8, 2021Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Measles, Mumps, and Rubella (MMR) Immunity in College Students

Inclusion Criteria

Exclusion Criteria

Prospective Clinical Registry for Evaluation of Exanthematous Infections and Coinfections

Vaccine Campaign Effects on General Hospital Admissions and Mortality Among Children

Co-administration Study of OCV, TCV and MR

Participant Centered Active Surveillance for Adverse Event Following Measles Immunization in Gedeo Zone, Ethiopia, 2022. A Multi-center Open-label Randomized Control Trial

Safety and Immunogenicity Study of Live Attenuated Mumps Vaccines in Healthy Infants

Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella (MMR) Vaccine